<!DOCTYPE html>

<html lang="fa">
<meta content="text/html;charset=utf-8" http-equiv="content-type"/>
<head><title>Botulinum toxin for cosmetic indications: Treatment of specific sites</title><link href="/d/css/bootstrap.min.css" rel="stylesheet"/><link href="/d/css/icofont.min.css" rel="stylesheet"/><link href="/d/css/classy-nav.min.css" rel="stylesheet"/><link href="/d/css/animate.css" rel="stylesheet"/><link href="/d/css/owl.carousel.css" rel="stylesheet"/><link href="/d/css/magnific-popup.css" rel="stylesheet"/><link href="/d/css/owl.theme.default.min.css" rel="stylesheet"/><link href="/d/css/style.css" rel="stylesheet"/><link href="/d/css/rtl_edited.css" rel="stylesheet"/><link href="/d/css/responsive.css" rel="stylesheet"/><link href="https://medilib.ir/uptodate_assets/main.css" rel="stylesheet">
<style>

#myUL {
  list-style-type: none;
  padding: 0;
  margin: 0;
}

#myUL li a {
  border: 1px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #f6f6f6;
  padding: 12px;
  text-decoration: none;
  font-size: 16px;
  color: black;
  display: block
}

#myUL li a:hover:not(.header) {
  background-color: #eee;
}

#searchResult {

  list-style-type: none;
  padding: 0;
  padding-right: 20px;
}

#searchResult li a {
  border: .5px solid #ddd;
  margin-top: -1px; /* Prevent double borders */
  background-color: #79bc21;
  padding: 7px;
  text-decoration: none;
  font-size: 14px;
  color: white;
  display: block
}

#searchResult li a:hover:not(.header) {
  background-color: #222;
}


#txtHint   {
  position: absolute;
  text-shadow: none;
  width: 100%;
  margin-top: -15px;
  padding-right: 10px;

  filter: alpha(opacity=95);
  -moz-opacity: 0.95;
  opacity: 1;
  z-index: 200;
}
.countBubl {
  background:#eb0029;
  color:#fff;
  padding:5px;
  margin-top: 50%;

}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(2) {
 width: 55%;
 padding-left: 20px;
}
.uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > span:nth-child(1) > img:nth-child(3) {
 width: 20%;
}
 #Uptodate_image {
      width: 50%;
  }#uptodate-area {
      /*z-index: 99;*/
  }
#uptodate-area > div:nth-child(1) > div:nth-child(1) > div:nth-child(1) > div:nth-child(2) {
 margin-left: 10px;
 margin-bottom: 6%;
}
@media (max-width: @screen-xs) {
    .countBubl {
        font-size: 4px ;
    }
    #uptodate_version {
        font-size: 4px ;
    }
}

@media (max-width: @screen-sm) {
    .countBubl {
        font-size: 14px ;
    }
}
@media  all and(max-width: 820) {
    #Uptodate_image {
        width: 80% ;
    }#uptodate-area {
        z-index: 99;
    }
}@media  all and (min-width: 820) and(max-width: 88820){
    #Uptodate_image {
        width: 100% !important;
    }
    .countBubl {
        font-size: 4px ;
    }
}
div.col-md-3:nth-child(3) {
 margin-top: 6%;
}

div.col-md-3:nth-child(3) > img:nth-child(1) {
 width: 100%;
 margin-left: 11px;
}

</style>
<style media="screen" type="text/css">
  .goback {
    width: 200px;
    height: 40px;
    line-height: 40px;
    position: fixed;
    display: none;
    font-size: 15px;
    background: #71c0fa;
    z-index: 1000;
    text-align: center;
    color: #ffffff;
    -webkit-border-radius: 1px;
    -moz-border-radius: 1px;
    border-radius: 50px;
    bottom: 3.8%;
    right: 2%;
}
  .buyPackage {
  width: 100px;
  height: 100px;
  line-height: 40px;
  position: fixed;
  display: none;
  font-size: 10px;
  background: #fa759e;
  z-index: 1000;
  text-align: center;
  color: #ffffff;
  -webkit-border-radius: 1px;
  -moz-border-radius: 1px;
  border-radius: 10px;
  top: 150px;
  right: 2%;
  text-align: center;
}
.uptodate-area {
  /*background-image: url(../../assets/img/news-letter-bg.jpg);*/
  background-position: center center;
  background-size: cover;
  background-repeat: no-repeat;
    background-attachment: fixed;
  position: relative;
}
.uptodate-area::before {
  content: '';
  position: absolute;
  left: 0;
  padding-top: 100px;
  width: 100%;
}
#references{
  display: none;
}
</style>
<style>
section.sticky {
  position: sticky;
  top: 0;
  background-color: #fff !important;
  /*z-index: 100;*/
  /*padding-top: 80px;*/

}
.m4inb{
    border: solid !important;
  }

  .newsletter-area::before {
       background: unset !important;
  }
p {
    color: #555;
}
</style>

<meta content="" name="description"/>
<link href="/d/img/favicon.png" rel="icon" type="image/png"/>
</link></head>
<body>
<!-- Start Main Menu Area -->

<br/>
<br/>
<br/>
<br/>
<div class="container">
<div class="row">
</div>
</div>




<section class="teacher-area ptb-10">
<div class="container">
</div>

<section class="course-details-area ptb-60">
<div class="container">
<div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
<h1 style="text-align:center">Botulinum toxin for cosmetic indications: Treatment of specific sites</h1>
<div class="utdArticleSection utdStyle" id="topicContent"><div id="topicTitle">Botulinum toxin for cosmetic indications: Treatment of specific sites</div> <div class="authorSectionElem"><div class="authorsElementsLeft"><dl id="topicContributors"><dt><span> </span>Author:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jean Carruthers, MD, FRCSC</a></dd><dt><span> </span>Section Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Jeffrey S Dover, MD, FRCPC</a></dd><dt><span> </span>Deputy Editor:</dt><dd><a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">Abena O Ofori, MD</a></dd></dl></div><div class="authorsElementsRight"><div id="literatureReviewDate"><div class="litReviewSingleLine"><bdi><span class="emphasis">Literature review current through:</span> Jan 2024.</bdi></div><div class="litReviewSingleLine"><bdi><span class="emphasis">This topic last updated:</span> Nov 19, 2021.</bdi></div></div></div></div><div id="topicWhatsNewContainer"></div><div id="topicText"><p class="headingAnchor" id="H1727983"><span class="h1">INTRODUCTION</span><span class="headingEndMark"> — </span>Botulinum toxin is an injectable neuromodulator derived from neurotoxins produced by <em>Clostridium botulinum</em>, the bacterium responsible for botulism. As a result of the ability of the toxin to inhibit neurotransmission between peripheral nerves and muscle tissue, botulinum toxin is an effective treatment for aesthetic and medical concerns that are exacerbated by muscle contraction. Although US Food and Drug Administration (FDA) approval for the cosmetic use of <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> is limited to glabellar lines, lateral canthal lines (crow's feet), and forehead lines and FDA approval for <a class="drug drug_general" data-topicid="15586" href="/d/drug information/15586.html" rel="external">incobotulinumtoxinA</a>, <a class="drug drug_general" data-topicid="9195" href="/d/drug information/9195.html" rel="external">abobotulinumtoxinA</a>, and <a class="drug drug_general" data-topicid="120299" href="/d/drug information/120299.html" rel="external">prabotulinumtoxinA</a> remains limited to the treatment of glabellar lines, injectable botulinum toxin is widely used for other cosmetic indications.</p><p>Examples of aesthetic concerns on the face and neck that can be improved with botulinum toxin will be reviewed here. The mechanism of action, available formulations, general use, and adverse effects of botulinum toxin in cosmetic settings are discussed separately. (See  <a class="medical medical_review" href="/d/html/13643.html" rel="external">"Overview of botulinum toxin for cosmetic indications"</a>.)</p><p class="headingAnchor" id="H1727991"><span class="h1">GENERAL PRINCIPLES</span><span class="headingEndMark"> — </span>The human face is composed of a complex array of muscles that act in concert to create facial expressions and fulfill vital functions. Clinicians with a thorough understanding of facial anatomy and the functional relationships between muscles in the face and neck can safely use botulinum toxin to selectively weaken specific muscles, resulting in favorable cosmetic results. An illustration of normal facial musculature is provided  (<a class="graphic graphic_figure graphicRef58011" href="/d/graphic/58011.html" rel="external">figure 1</a>). </p><p>Appropriate candidates for botulinum toxin injection are patients with specific cosmetic concerns that can be alleviated by local muscle weakening and who lack contraindications to therapy. Patients between the ages of 30 and 50 years often achieve the most benefit from treatment; a greater proportion of rhytides in older patients may be due to loss of skin elasticity, which is not alleviated by botulinum toxin alone [<a href="#rid1">1,2</a>]. (See  <a class="medical medical_review" href="/d/html/13643.html" rel="external">"Overview of botulinum toxin for cosmetic indications", section on 'Contraindications'</a>.)</p><p>Once patients have been determined to be good candidates for botulinum toxin therapy, care must be taken to ensure that the anatomic placement of injections is correct and that the doses used are appropriate based upon the treatment site and patient-specific characteristics (eg, anatomic variation, patient sex, and preferences regarding the magnitude of effect). Conservative treatment is preferred; improper placement of injections or an excessive dose of botulinum toxin can result in cosmetic or functional defects that persist for months. </p><p>There are seven serotypes of botulinum toxin, two of which are available for clinical use (botulinum toxin type A and botulinum toxin type B). Botulinum toxin type A has been the most extensively studied for cosmetic indications and is the serotype that will be reviewed here. A variety of formulations of botulinum toxin type A are available for clinical use worldwide; the agents most commonly used in North America include <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> (Botox, Botox Cosmetic), <a class="drug drug_general" data-topicid="15586" href="/d/drug information/15586.html" rel="external">incobotulinumtoxinA</a> (Xeomin, Bocouture), <a class="drug drug_general" data-topicid="9195" href="/d/drug information/9195.html" rel="external">abobotulinumtoxinA</a> (Dysport), and <a class="drug drug_general" data-topicid="120299" href="/d/drug information/120299.html" rel="external">prabotulinumtoxinA</a> (Jeuveau, Nuceiva). <strong>Dosing is not interchangeable among the different formulations of botulinum toxin type A; all examples of doses provided below are specific to the form of botulinum toxin mentioned.</strong></p><p>The general principles of botulinum toxin therapy for cosmetic indications are discussed in greater detail separately. (See  <a class="medical medical_review" href="/d/html/13643.html" rel="external">"Overview of botulinum toxin for cosmetic indications"</a>.)</p><p class="headingAnchor" id="H4080941"><span class="h1">UPPER FACE</span><span class="headingEndMark"> — </span>The muscles of movement and expression in the upper face include the frontalis, a large quadrilateral muscle that raises the eyebrows and skin over the root of the nose and draws the scalp forward, and the glabellar complex, a group of brow-associated muscles (corrugator supercilii, procerus, depressor supercilii, and orbicularis oculi muscles) used primarily for expression, especially anger, displeasure, or concern  (<a class="graphic graphic_figure graphicRef58011" href="/d/graphic/58011.html" rel="external">figure 1</a>). </p><p>Hyperactivity or repetitive use of these muscles over time leads to the formation of skin lines that are exacerbated during muscle contraction (dynamic rhytides). Weakening of the responsible muscles with botulinum toxin can smooth vertical glabellar rhytides (related to the contraction of muscles in the glabellar complex), horizontal forehead rhytides (induced by frontalis muscle contraction), and periorbital lateral canthal rhytides (associated with contraction of the lateral orbicularis oculi muscle).</p><p class="headingAnchor" id="H4080948"><span class="h2">Glabellar rhytides</span><span class="headingEndMark"> — </span>The first report of the use of botulinum toxin for a cosmetic purpose focused on the treatment of glabellar rhytides [<a href="#rid3">3</a>]. Glabellar lines  (<a class="graphic graphic_picture graphicRef71122" href="/d/graphic/71122.html" rel="external">picture 1</a>) are caused by contraction of the corrugator supercilii and orbicularis oculi muscles, which move the brow medially, and the procerus and depressor supercilii muscles, which pull the brow inferiorly. The corrugator supercilii and procerus muscles are typically targeted during treatment. Beneficial effects from injection last for at least three months in most patients  (<a class="graphic graphic_picture graphicRef64007" href="/d/graphic/64007.html" rel="external">picture 2A</a>) [<a href="#rid4">4,5</a>].</p><p>Although the precise placement and number of injections is influenced by anatomical differences among patients, five injection sites are commonly used to weaken the brow depressors in the treatment of glabellar rhytides  (<a class="graphic graphic_picture graphicRef65462" href="/d/graphic/65462.html" rel="external">picture 2B</a>). All injections should be placed above the supraorbital rim to reduce the risk of upper eyelid ptosis. We typically inject into the corrugator supercilii muscles above the inner canthi bilaterally (30 percent of total dose per injection) followed by a third medial injection into the procerus (20 percent of total dose). We have found that the fourth and fifth injections are particularly beneficial in patients in whom the brow musculature leads to the appearance of horizontal eyebrows. These injections are placed 1 cm above the supraorbital rim in the mid-pupillary line (10 percent of total dose per injection) but can also be sited above the lateral canthus, above the bony rim. </p><p>The standard doses recommended by the manufacturers of <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> (Botox Cosmetic), <a class="drug drug_general" data-topicid="15586" href="/d/drug information/15586.html" rel="external">incobotulinumtoxinA</a> (Xeomin), <a class="drug drug_general" data-topicid="120299" href="/d/drug information/120299.html" rel="external">prabotulinumtoxinA</a> (Jeuveau), and <a class="drug drug_general" data-topicid="9195" href="/d/drug information/9195.html" rel="external">abobotulinumtoxinA</a> (Dysport) are total doses of 20 units, 20 units, 20 units, and 50 units, respectively. However, the doses required to achieve desired results vary among patients due to differences in muscle mass or muscle activity. Males typically have greater muscle mass in the brow than females, and thus require higher doses to achieve satisfactory results [<a href="#rid4">4,5</a>]. We found the following results in two randomized dose-finding trials of 80 patients with glabellar rhytides:</p><p class="bulletIndent1"><span class="glyph">●</span>A dose of 10 units of <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> was significantly less effective than 20, 30, or 40 units for the treatment of glabellar lines in women and was associated with a higher risk of relapse after four months [<a href="#rid4">4</a>].</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Among male patients, doses of 40, 60, or 80 units of <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> were more effective and induced longer lasting benefit than treatment with 20 units [<a href="#rid5">5</a>].</p><p></p><p>The incidence of adverse effects was similar among treatment groups in both trials. Treatment-related adverse effects were transient and mild to moderate, and included symptoms such as headache, symptoms of tension or heaviness in the forehead or brow, ptosis of the brow, and muscle spasms in the forehead.</p><p>We typically initiate treatment with approximately 30 units of <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> in women and 60 units in men, with subsequent increases in dose up to 50 or 100 units, respectively, based upon response. Lower initial doses (10 to 30 units for women and 20 to 40 units for men) have also been used for glabellar rhytides [<a href="#rid6">6</a>]. For treatment with <a class="drug drug_general" data-topicid="9195" href="/d/drug information/9195.html" rel="external">abobotulinumtoxinA</a>, dose ranges of 30 to 70 units in women and 50 to 80 units in men have been suggested by some authors [<a href="#rid7">7</a>].</p><p>We have found that some patients benefit from a total of seven injections, with the additional two injections placed into the lateral orbicularis oculi muscle. These injections are performed above the lateral canthus or into the lateral end of the eyebrow, and can result in further reductions in the glabellar lines and improved positioning of the lateral brow. We typically use 4 to 8 units of <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> in these sites. </p><p class="headingAnchor" id="H4080955"><span class="h2">Horizontal forehead rhytides</span><span class="headingEndMark"> — </span>Contraction of the frontalis muscle eventually leads to the formation of horizontal creases in the forehead that are exacerbated during brow elevation  (<a class="graphic graphic_picture graphicRef50165" href="/d/graphic/50165.html" rel="external">picture 3A</a>). Botulinum toxin injection can reduce the appearance of these lines both during muscle contraction and at rest  (<a class="graphic graphic_picture graphicRef71162" href="/d/graphic/71162.html" rel="external">picture 4</a>) [<a href="#rid8">8</a>]. In our experience, the beneficial effects of treatment in this area typically last between three and six months.</p><p>The goal of treatment is to weaken but not completely paralyze the frontalis muscle. Patients with favorable responses have reduced forehead rhytides and remain able to elevate the brows, albeit to a lesser extent. Treatment of the frontalis muscle for horizontal rhytides should always be performed in conjunction with treatment of the brow depressors. Weakening of the frontalis muscle without corresponding inhibition of the brow depressors can result in unopposed action of the depressors and a lowered, angry-looking brow.</p><p>In a randomized, dose-finding trial that investigated the efficacy of treatment with <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> in 59 women with moderate to severe forehead rhytides, total doses of 16, 32, and 48 units injected into the brow elevators and depressors (frontalis, procerus, and lateral orbicularis oculi muscles) (8, 16, and 24 units injected into the frontalis) all were effective for achieving improvement [<a href="#rid8">8</a>]. Of note, a statistically significant trend towards longer durations of response was observed with increasing doses. Sixteen weeks after treatment, wrinkle severity at maximum muscle contraction and repose had returned to baseline in 75, 58, and 35 percent of patients in the 16, 32, and 48 unit treatment groups, respectively. The number of adverse effects was similar among treatment groups and no serious adverse effects occurred during the course of the trial. </p><p>As in the glabellar area, patient-specific characteristics influence botulinum toxin administration. We typically perform five injections in patients with broad foreheads (greater than 12 cm between the temporal fusion lines at the mid-brow) and four injections in patients with narrower foreheads, using a slightly lower total dose in the latter  (<a class="graphic graphic_picture graphicRef75187" href="/d/graphic/75187.html" rel="external">picture 3B</a>). The total amount of <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> we inject into the frontalis muscle usually ranges between 10 and 15 units. Treatment with 40 units (range 20 to 60 units) of <a class="drug drug_general" data-topicid="9195" href="/d/drug information/9195.html" rel="external">abobotulinumtoxinA</a> in four injection sites has been utilized by some authors [<a href="#rid7">7</a>].</p><p>Injections into the frontalis muscle must be placed carefully to avoid undesirable cosmetic results. We inject horizontally across the mid-forehead, approximately 2 to 3 cm above the eyebrows. The use of excessive doses or placement of injections too close to the brow can result in inhibition of facial expression and brow ptosis.</p><p class="headingAnchor" id="H4080962"><span class="h2">Lateral canthal rhytides (crow's feet)</span><span class="headingEndMark"> — </span>The orbicularis oculi muscle complex plays an important role in eyelid closure. Contraction of the lateral fibers of the orbicularis oculi muscle also produces lines (also known as crow's feet) that radiate from the lateral canthus and are exacerbated during smiling  (<a class="graphic graphic_picture graphicRef59956" href="/d/graphic/59956.html" rel="external">picture 5A</a>). Botulinum toxin injection into this area can reduce the appearance of these rhytides  (<a class="graphic graphic_picture graphicRef50135" href="/d/graphic/50135.html" rel="external">picture 6</a>) [<a href="#rid1">1,9-11</a>]. </p><p>A dose-dependent effect of treatment has been reported. In one randomized trial in which 157 patients with moderate to severe lateral canthal rhytides were treated with varying doses of <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> or placebo, the rates of treatment response remained significantly greater than placebo for longer periods of time with higher doses than with lower doses [<a href="#rid9">9</a>]. Patients treated with 12 or 18 units per side maintained significant improvement at maximal smile for at least 150 days after treatment, while the difference between placebo and treatment groups was no longer statistically significant in patients treated with 3 or 6 units at 60 or 150 days, respectively. The authors also commented that the magnitude of effect appeared to be higher in patients treated with the higher doses of onabotulinumtoxinA. </p><p>Because the orbicularis oculi muscle is diffusely innervated, multiple injections are required to weaken the muscle effectively. We typically inject 12 to 15 units of <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> per periocular region divided into two to four injection sites  (<a class="graphic graphic_picture graphicRef54110" href="/d/graphic/54110.html" rel="external">picture 5B</a>).</p><p>A separate randomized trial of <a class="drug drug_general" data-topicid="9195" href="/d/drug information/9195.html" rel="external">abobotulinumtoxinA</a> injections for lateral canthal rhytides found that doses of 15, 30, and 45 units per side were all effective, but detected a trend towards increased response rates with doses of 30 and 45 units [<a href="#rid1">1</a>]. Use of a total dose of 30 units, divided into three injection points per side, has been suggested by some authors [<a href="#rid7">7</a>]. </p><p><a class="drug drug_general" data-topicid="15586" href="/d/drug information/15586.html" rel="external">IncobotulinumtoxinA</a> has also been used successfully for the treatment of periocular rhytides [<a href="#rid10">10</a>].</p><p>In order to minimize the risk for complications, all injections should be placed laterally to the lateral orbital rim and should be performed while the face is at rest  (<a class="graphic graphic_picture graphicRef54110" href="/d/graphic/54110.html" rel="external">picture 5B</a>). Medial injections or injections performed while the patient is smiling can result in eyelid droop and lip ptosis, respectively. Additionally, bruising is easily induced in the periorbital area; performing only a few superficial injections may reduce this risk. The application of manual pressure immediately after needle withdrawal may also reduce the occurrence of bruising.</p><p class="headingAnchor" id="H4080969"><span class="h2">Brow lift</span><span class="headingEndMark"> — </span>Brow ptosis  (<a class="graphic graphic_picture graphicRef71706" href="/d/graphic/71706.html" rel="external">picture 7</a>), a common feature of aging, can result in facial features at rest that mimic angry or scowling facial expressions. Because the shape and height of the eyebrow are controlled by the opposing action of the frontalis muscle, which elevates the brow, and the muscles that depress the brow, botulinum toxin can be used to improve brow ptosis.</p><p>The nonsurgical brow lift with botulinum toxin was discovered serendipitously during treatment of glabellar frown lines, as it became evident that treated patients exhibited central and medial brow elevation [<a href="#rid12">12-14</a>]. Elevation of the brow was initially thought to be due to inactivation of the medial depressor muscles. However, weakening of the lower medial frontalis muscle due to local diffusion of botulinum toxin may be responsible for improved resting tone in the rest of the frontalis musculature and subsequent brow elevation [<a href="#rid14">14</a>]. </p><p>Typically, brow elevation is best seen when the glabellar area is treated without concurrent injection of frontalis muscle for horizontal forehead lines [<a href="#rid14">14</a>]. Additionally, lateral eyebrow elevation has been reported after injections limited to the superolateral orbicularis oculi muscle (tail of the eyebrow) [<a href="#rid15">15,16</a>]. </p><p class="headingAnchor" id="H4080976"><span class="h2">Hypertrophic orbicularis oculi</span><span class="headingEndMark"> — </span>Botulinum toxin can be used to widen the ocular aperture by weakening the orbicularis oculi muscle complex, resulting in the appearance of a wider, rounder eye during smiling and at rest. </p><p>We evaluated the use of <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> for this indication in a randomized, split-face trial of 15 women [<a href="#rid17">17</a>]. Injection of 2 units of botulinum toxin subdermally into the lower eyelid, 3 mm below the ciliary margin, increased palpebral aperture in 40 percent of patients (average increase in palpebral aperture was 0.5 mm at rest and 1.3 mm at maximum smile). Similar injections on the contralateral side given in combination with 12 units of onabotulinumtoxinA into the lateral orbital area enhanced the effect; increases in palpebral aperture occurred in 86 percent of patients (mean increase in palpebral aperture of 1.8 mm at rest and 2.9 mm at full smile). Both treatment regimens were well tolerated. </p><p>Doses of more than 4 units of botulinum toxin in the lower eyelid are not recommended, due to an increased risk for adverse effects [<a href="#rid18">18</a>]. Poor candidates for this procedure include patients who respond poorly to a preinjection snap test (lower eyelid does not return quickly to the globe after abrupt release from manual downward retraction), patients who are susceptible to lower lid puffiness, patients who have had ablative laser resurfacing of the lower eyelid, or patients who have had lower lid blepharoplasty without concomitant canthopexy to support the normal eyelid position.</p><p class="headingAnchor" id="H4080990"><span class="h1">MID-FACE</span><span class="headingEndMark"> — </span>Botulinum toxin injection is useful for the treatment of several cosmetic concerns in the mid-facial area  (<a class="graphic graphic_figure graphicRef58011" href="/d/graphic/58011.html" rel="external">figure 1</a>). Injection into the upper nasalis muscle can soften wrinkling on the dorsal or lateral nose (also known as "bunny lines")  (<a class="graphic graphic_picture graphicRef52791 graphicRef64576" href="/d/graphic/52791.html" rel="external">picture 8A-B</a>). We typically utilize 2 to 4 units of <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> per side  (<a class="graphic graphic_picture graphicRef67933" href="/d/graphic/67933.html" rel="external">picture 9</a>); doses of 10 to 20 units of <a class="drug drug_general" data-topicid="9195" href="/d/drug information/9195.html" rel="external">abobotulinumtoxinA</a> have also been used for this purpose [<a href="#rid7">7</a>]. </p><p>In our practice, we have found that injection of 5 to 10 units of <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> into the lower nasalis is useful for reducing nostril flare. A small amount of onabotulinumtoxinA (2 to 3 units) into the depressor septi nasi muscle can also be used to slightly elevate the nasal tip. </p><p>Prominent nasolabial folds, which extend from the lateral nasal alae to the skin lateral to the mouth  (<a class="graphic graphic_picture graphicRef77905" href="/d/graphic/77905.html" rel="external">picture 10</a>), are common cosmetic concerns that are often managed with injectable soft tissue fillers and laser resurfacing. Very small amounts of botulinum toxin (eg, 1 unit of <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a>) into each lip elevator complex above the nasofacial groove can collapse the upper nasolabial fold. However, this procedure may also vertically lengthen the upper lip, a feature associated with aging. Thus, we only consider this procedure in patients with naturally short upper lips. Treatment may be most effective when combined with soft tissue fillers or laser resurfacing. (See  <a class="medical medical_review" href="/d/html/16532.html" rel="external">"Injectable soft tissue fillers: Overview of clinical use"</a> and  <a class="medical medical_review" href="/d/html/16399.html" rel="external">"Injectable soft tissue fillers: Temporary agents"</a> and  <a class="medical medical_review" href="/d/html/13652.html" rel="external">"Injectable soft tissue fillers: Permanent agents"</a> and  <a class="medical medical_review" href="/d/html/13629.html" rel="external">"Ablative laser resurfacing for skin rejuvenation"</a>.)</p><p>Care should be taken to select patients who are most likely to benefit cosmetically from this procedure and to avoid overtreatment; in our experience, the effects of botulinum toxin injection in this site can last for up to six months. Injections should not be placed directly into the nasolabial fold, as this may result in an asymmetrical smile or lip ptosis [<a href="#rid19">19</a>].</p><p class="headingAnchor" id="H1727944"><span class="h1">LOWER FACE</span><span class="headingEndMark"> — </span>Botulinum toxin injection in the lower face is commonly performed  (<a class="graphic graphic_figure graphicRef58011" href="/d/graphic/58011.html" rel="external">figure 1</a>) [<a href="#rid19">19,20</a>]. However, injections must be given with caution. Improper injection in the perioral area may result in a flaccid cheek, an incompetent mouth, or an asymmetrical smile. In addition, perioral injections generally are not recommended for singers or musicians who play wind instruments, or others who require intense use of the perioral musculature. </p><p class="headingAnchor" id="H4080997"><span class="h2">Perioral lip rhytides</span><span class="headingEndMark"> — </span>Vertical perioral rhytides  (<a class="graphic graphic_picture graphicRef50746" href="/d/graphic/50746.html" rel="external">picture 11A</a>) are common cosmetic concerns that may be induced by repetitive contraction of the orbicularis oris muscle, volume loss, photodamage, and other factors [<a href="#rid21">21</a>]. Cosmetic fillers or laser resurfacing are often used to treat perioral rhytides. However, the results of these procedures are temporary, and normal perioral animation likely contributes to the fairly rapid recurrence of rhytides [<a href="#rid22">22</a>]. </p><p>The muscular contribution to perioral rhytides can be treated with the injection of small doses of botulinum toxin adjacent to the vermillion border in the areas of rhytides lateral to the Cupid's bow area of the lip. In a series of 18 patients treated with varying doses of <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a>, smoothing of perioral rhytides and favorable eversion of the upper lip were detected after treatment [<a href="#rid23">23</a>].</p><p>We often inject 2 units of <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> per lip quadrant, divided into two injection sites within each quadrant  (<a class="graphic graphic_picture graphicRef62503" href="/d/graphic/62503.html" rel="external">picture 11B</a>). Doses of <a class="drug drug_general" data-topicid="9195" href="/d/drug information/9195.html" rel="external">abobotulinumtoxinA</a> suggested by other authors include 8 units divided into four injection points for the upper lip and 4 units divided into two injection points in the lower lip [<a href="#rid7">7</a>]. Combination treatment with soft tissue fillers may result in improved efficacy [<a href="#rid24">24,25</a>]. (See  <a class="medical medical_review" href="/d/html/16532.html" rel="external">"Injectable soft tissue fillers: Overview of clinical use"</a> and  <a class="medical medical_review" href="/d/html/16399.html" rel="external">"Injectable soft tissue fillers: Temporary agents"</a> and  <a class="medical medical_review" href="/d/html/13652.html" rel="external">"Injectable soft tissue fillers: Permanent agents"</a>.)</p><p>Significant lip weakening is a risk of this procedure; when performed appropriately, some patients may have altered lip proprioception after treatment, but functions such as eating, drinking, and singing should not be affected. Placing injections superficially and utilizing conservative dosing may help to minimize the risks of treatment. However, avoidance of this procedure should be considered in patients who require intense use of the perioral musculature, such as professional singers and orators or musicians who play wind instruments.</p><p>Injection of the oral commissures (corners of the lip) and the midline area should be avoided, as it may result in a drooping lateral lip and flattening of the Cupid's bow, respectively [<a href="#rid20">20</a>].</p><p class="headingAnchor" id="H4081004"><span class="h2">Mouth frown and melomental folds</span><span class="headingEndMark"> — </span>The depressor anguli oris (DAO) muscle pulls the corner of the mouth downward in opposition to the action of the zygomaticus major and zygomaticus minor muscles. When the lateral corners of the mouth angle downward, the mouth takes on a frowning, unpleasant expression  (<a class="graphic graphic_picture graphicRef76339" href="/d/graphic/76339.html" rel="external">picture 12</a>). Botulinum toxin can be used to weaken the DAO and subtly reset muscular balance, allowing the zygomaticus to elevate the corners of the mouth and return them to a horizontal position. As with perioral lip rhytides, treatment of this area is not recommended in patients in whom intense use of the perioral musculature is essential (eg, professional singers and wind instrument musicians).</p><p>In order to avoid unintentional weakening of the nearby depressor labii inferioris muscle during the treatment of mouth frown, we inject at the posterior margin of the DAO muscle, close to the anterior margin of the masseter. We usually utilize 2 to 3 units of <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> per side. Because the upward pull of the mentalis muscle also contributes to mouth frown, we perform additional 3 unit injections into each insertion point of the mentalis muscle  (<a class="graphic graphic_picture graphicRef69123" href="/d/graphic/69123.html" rel="external">picture 13</a>). </p><p>Contraction of the DAO muscle also exacerbates the melomental folds (also known as marionette lines)  (<a class="graphic graphic_picture graphicRef55290" href="/d/graphic/55290.html" rel="external">picture 14</a>). Melomental folds have traditionally been corrected with soft tissue filling agents, but the benefit from treatment is generally short-lived. Treatment with botulinum toxin may potentiate the results of soft tissue filler injections by reducing the mobility of the underlying musculature. In one split-face randomized trial of 22 patients with melomental folds, photographic assessments revealed longer durations of effect after combination therapy than after treatment with a filling agent alone (median time to return to baseline of 39 weeks versus 32.5 weeks) [<a href="#rid26">26</a>]. However, the difference in the rate of relapse was not significant on live clinician assessment. Additional studies are necessary to explore the value of combination therapy in this setting. (See  <a class="medical medical_review" href="/d/html/16532.html" rel="external">"Injectable soft tissue fillers: Overview of clinical use"</a> and  <a class="medical medical_review" href="/d/html/16399.html" rel="external">"Injectable soft tissue fillers: Temporary agents"</a> and  <a class="medical medical_review" href="/d/html/13652.html" rel="external">"Injectable soft tissue fillers: Permanent agents"</a>.)</p><p>For the treatment of melomental folds, we inject small amounts (2 to 5 units) of <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> into the posterior margin of each DAO immediately above the mandible. Injections placed too anterior or too high can cause ipsilateral weakness of the depressor labii inferioris muscle, flattening of the lower lip contour, mouth incompetence, and reduced oral sphincter function.</p><p>When using <a class="drug drug_general" data-topicid="9195" href="/d/drug information/9195.html" rel="external">abobotulinumtoxinA</a> for mouth frown or melomental folds, injections of 2.5 to 10 units per side into the lower one-third of the DAO have been suggested [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H4081011"><span class="h2">Mental crease and peau d'orange chin</span><span class="headingEndMark"> — </span>Contraction of the mentalis muscle produces a horizontal crease between the lower lip and the prominence of the chin  (<a class="graphic graphic_picture graphicRef80633" href="/d/graphic/80633.html" rel="external">picture 15</a>). In our experience, small doses of botulinum toxin injected into the mentalis muscle just anterior to the bony mentum on each side of the midline soften the indentation. We often use 3 to 5 units of <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> per side. Injection at the level of the mental crease should be avoided, as this can weaken the orbicularis oris muscle, creating mouth incompetence that can last for up to six months.</p><p>In patients with local loss of dermal collagen and subcutaneous fat on the chin due to aging, contraction of the mentalis muscle can contribute to the appearance of multiple dimpled areas on the chin (peau d'orange chin)  (<a class="graphic graphic_picture graphicRef76750" href="/d/graphic/76750.html" rel="external">picture 16</a>). Peau d'orange chin can also occur during or after recovery from Bell's palsy. Botulinum toxin injection into the mentalis muscle at the prominence of the chin (distal to the orbicularis oris) with or without soft tissue fillers can ameliorate the peau d'orange chin  (<a class="graphic graphic_picture graphicRef75756" href="/d/graphic/75756.html" rel="external">picture 17</a>). We typically use 5 to 10 units of <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> as one or two injections  (<a class="graphic graphic_picture graphicRef57846" href="/d/graphic/57846.html" rel="external">picture 18</a>). Doses of 5 to 20 units of <a class="drug drug_general" data-topicid="9195" href="/d/drug information/9195.html" rel="external">abobotulinumtoxinA</a> divided into two injections into the mentalis muscle also have been used for this purpose [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H4081018"><span class="h2">Masseteric hypertrophy</span><span class="headingEndMark"> — </span>Excessive hypertrophy of the masseter muscle, caused by bruxism (teeth grinding), temporomandibular joint disorders, misaligned jaws, or genetic background, leads to a square appearance to the jaw that may or may not be asymmetrical. Historically, persistent masseteric hypertrophy was treated surgically. </p><p>The efficacy of botulinum toxin injection for facial sculpting in patients with masseteric hypertrophy is supported by case reports and uncontrolled studies [<a href="#rid27">27-30</a>]. Botulinum injected into each masseter effectively sculpts the jawline, reducing muscle thickness by up to 50 percent for three to six months or longer [<a href="#rid31">31-34</a>] and easing symptoms of bruxism [<a href="#rid34">34,35</a>]. Mean muscle size decreases over repeated treatments, allowing for smaller doses as treatment progresses [<a href="#rid36">36</a>]. The potential adverse effects of treatment include temporarily reduced bite strength, speech disturbances, muscle pain, facial asymmetry, and prominent zygoma [<a href="#rid37">37</a>]. </p><p class="headingAnchor" id="H485525"><span class="h2">Gingival (gummy) smile</span><span class="headingEndMark"> — </span>Some patients find display of a significant portion of the upper gum during smiling undesirable. The terms "gingival smile" or "gummy smile" are used to describe exposure of more than 3 mm of the gum during smiling [<a href="#rid38">38</a>]. Surgical and orthodontic interventions have been used to manage this condition; botulinum toxin offers a nonsurgical treatment option [<a href="#rid38">38-40</a>]. </p><p>Injections of <a class="drug drug_general" data-topicid="9195" href="/d/drug information/9195.html" rel="external">abobotulinumtoxinA</a> into the levator labii superioris alaeque nasi muscles, zygomaticus muscles, or both areas (dependent upon smile characteristics) resulted in a decrease in gum display in all 16 patients in one uncontrolled study [<a href="#rid38">38</a>]. Adverse effects of treatment were mild and included smile abnormalities in two patients that were corrected with subsequent injections. In a separate uncontrolled study of 30 patients, injection of 2.5 units of <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> into overlapping points of the levator labii superioris alaeque nasi and levator labii superioris muscles and the overlapping points of the levator labii superioris and zygomaticus minor muscles (total of four injections) was effective for the treatment of gummy smile [<a href="#rid39">39</a>]. Treatment was generally well tolerated; reported adverse effects included pain at injection sites (four patients), headache (one patient), and dizziness (one patient).</p><p class="headingAnchor" id="H2948572155"><span class="h2">Lip augmentation (lip flip)</span><span class="headingEndMark"> — </span>Injection of botulinum into the orbicularis oris muscle can induce lip eversion, giving the appearance of lip augmentation. Cosmetically beneficial effects with injection of a total of 4 units of <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> into four sites along the vermillion border of the upper lip have been documented in case reports. Potential adverse effects include flattening of the upper vermillion border and reduced function of the lips [<a href="#rid41">41,42</a>].</p><p class="headingAnchor" id="H4081025"><span class="h1">NECK</span><span class="headingEndMark"> — </span>Although data are limited on the use of botulinum toxin for cosmetic concerns in the neck, botulinum toxin appears to be beneficial for vertical platysmal bands in patients who do not desire or who are poor candidates for surgical intervention (platysmaplasty), or in whom residual platysmal bands remain after neck rejuvenation surgery. We have also used botulinum toxin for the treatment of patients with horizontal lines on the neck.</p><p class="headingAnchor" id="H475150"><span class="h2">Platysmal bands</span><span class="headingEndMark"> — </span>Platysmal bands are vertical linear bands on the anterior neck that result from the separation and protrusion of the anterior edges of the platysma  (<a class="graphic graphic_picture graphicRef56880" href="/d/graphic/56880.html" rel="external">picture 19A</a>). Increased prominence of platysmal bands is associated with aging and is most evident during neck animation.</p><p>Data on the efficacy of botulinum toxin for platysmal bands are limited to case series and reports of clinical experience  (<a class="graphic graphic_picture graphicRef64533" href="/d/graphic/64533.html" rel="external">picture 19B</a>) [<a href="#rid43">43-47</a>]. In a series of 1500 patients treated with varying doses of <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> for platysmal bands, the majority of patients achieved good to excellent results [<a href="#rid43">43</a>]. The greatest benefit appeared to occur in patients with platysma muscle flaccidity, horizontal neck rhytides, and skin laxity that were graded as mild to moderate; 99 percent of patients with mild versions of these features achieved good to excellent results. </p><p>The most common adverse effect associated with the injection of platysmal bands is bruising [<a href="#rid43">43</a>]. Edema, erythema, muscle soreness, and neck discomfort may also occur. Neck weakness and dysphagia are rare adverse effects [<a href="#rid43">43</a>].</p><p>Although a wide range of doses of <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> has been utilized for the treatment of platysmal bands, we typically do not exceed 30 to 40 units of onabotulinumtoxinA in the neck per session, due to our concern for the induction of neck weakness or dysphagia with higher doses [<a href="#rid48">48</a>]. We often use 15 units of onabotulinumtoxinA per platysmal band, divided into three injection sites separated by 1 to 1.5 cm. Doses of 30 units of abobotulinumtoxin per platysmal band have been successfully utilized by some clinicians [<a href="#rid7">7</a>].</p><p class="headingAnchor" id="H475157"><span class="h2">Horizontal neck lines</span><span class="headingEndMark"> — </span>Horizontal neck lines  (<a class="graphic graphic_picture graphicRef69540" href="/d/graphic/69540.html" rel="external">picture 20A</a>) are caused by the attachments of superficial musculoaponeurotic system, a fibromuscular layer that envelops and connects muscles face and neck. We have had some success with softening the appearance of horizontal neck bands with botulinum toxin injection. We typically inject 10 to 20 units of <a class="drug drug_general" data-topicid="9161" href="/d/drug information/9161.html" rel="external">onabotulinumtoxinA</a> per session divided into multiple intradermal injections of 1 to 2 units spaced at 2 to 3 cm intervals  (<a class="graphic graphic_picture graphicRef81469" href="/d/graphic/81469.html" rel="external">picture 20B</a>). Injection beneath the dermis should be avoided to prevent bleeding from perforating veins and weakening of the underlying musculature utilized for swallowing.</p><p class="headingAnchor" id="H1093052851"><span class="h1">OTHER SITES</span><span class="headingEndMark"> — </span>Botulinum toxin may be useful for shoulder contouring. In two women, treatment with 50 units of botulinum toxin type A in each trapezius muscle led to slimming of the shoulders [<a href="#rid49">49</a>]. Injections into the trapezius were spaced by 1.5 to 2 cm. In addition, use of botulinum toxin injections to minimize the appearance of muscular calves has been documented in case reports [<a href="#rid50">50,51</a>]. Injections are placed into the medial head of the gastrocnemius muscle. Further study is necessary to clarify the efficacy and safety of these procedures.</p><p class="headingAnchor" id="H475164"><span class="h1">SUMMARY AND RECOMMENDATIONS</span></p><p class="bulletIndent1"><span class="glyph">●</span>Botulinum toxin is a neuromodulator that temporarily weakens muscles through inhibition of neurotransmission between peripheral nerves and muscle tissue. Botulinum toxin type A injections have been used extensively for the treatment of cosmetic concerns that are exacerbated by muscular activity. (See <a class="local">'Introduction'</a> above and <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Thorough knowledge of muscular anatomy and function is crucial for the effective and safe administration of botulinum toxin  (<a class="graphic graphic_figure graphicRef58011" href="/d/graphic/58011.html" rel="external">figure 1</a>). Improper administration can result in cosmetic disfigurement and functional deficits that persist for months. Dosing of botulinum toxin is not interchangeable among the different formulations. (See <a class="local">'General principles'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Botulinum toxin injection into the muscles that depress the brow results in improvements in glabellar rhytides  (<a class="graphic graphic_picture graphicRef64007 graphicRef65462" href="/d/graphic/64007.html" rel="external">picture 2A-B</a>). Males typically require higher doses of botulinum toxin due to greater muscle mass in this area. All injections should be placed above the supraorbital rim to reduce the risk of upper eyelid ptosis. (See <a class="local">'Glabellar rhytides'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Successful treatment of horizontal forehead rhytides requires simultaneous treatment of the frontalis muscle and the brow depressors  (<a class="graphic graphic_picture graphicRef50165 graphicRef75187" href="/d/graphic/50165.html" rel="external">picture 3A-B</a>). Injections placed too low in the frontalis muscle may result in brow ptosis. (See <a class="local">'Horizontal forehead rhytides'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Lateral canthal rhytides (crow's feet) can be successfully treated with multiple injections into the lateral orbicularis oculi muscle  (<a class="graphic graphic_picture graphicRef59956 graphicRef54110" href="/d/graphic/59956.html" rel="external">picture 5A-B</a>). Injections should be placed lateral to the orbital rim and should be performed while the facial musculature is at rest. (See <a class="local">'Lateral canthal rhytides (crow's feet)'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>Botulinum toxin injection can lead to improvement in perioral rhytides and melomental folds (marionette lines), particularly when used in combination with other rejuvenation procedures  (<a class="graphic graphic_picture graphicRef50746 graphicRef62503" href="/d/graphic/50746.html" rel="external">picture 11A-B</a> and <a class="graphic graphic_picture graphicRef55290" href="/d/graphic/55290.html" rel="external">picture 14</a>). Lip weakening is a risk of injection into the perioral area; avoidance of injection in this location should be considered in musicians who play wind instruments and others who require intense use of the perioral musculature. (See <a class="local">'Perioral lip rhytides'</a> above.)</p><p></p><p class="bulletIndent1"><span class="glyph">●</span>In addition to facial treatment, botulinum toxin can be used to improve the appearance of the neck. Patients with platysmal bands or horizontal neck lines may benefit from treatment  (<a class="graphic graphic_picture graphicRef56880 graphicRef64533" href="/d/graphic/56880.html" rel="external">picture 19A-B</a> and <a class="graphic graphic_picture graphicRef69540 graphicRef81469" href="/d/graphic/69540.html" rel="external">picture 20A-B</a>). (See <a class="local">'Neck'</a> above.)</p><p></p><p class="headingAnchor" id="H398407351"><span class="h1">ACKNOWLEDGMENT</span><span class="headingEndMark"> — </span>The UpToDate editorial staff acknowledges Alastair Carruthers, FRCPC, who contributed to an earlier version of this topic review.</p></div><div class="headingAnchor" id="references"><ol id="reference"><li><a class="nounderline abstract_t">Ascher B, Rzany BJ, Grover R. Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study. Dermatol Surg 2009; 35:1478.</a></li><li><a class="nounderline abstract_t">Carruthers JA, Lowe NJ, Menter MA, et al. A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines. J Am Acad Dermatol 2002; 46:840.</a></li><li><a class="nounderline abstract_t">Carruthers JD, Carruthers JA. Treatment of glabellar frown lines with C. botulinum-A exotoxin. J Dermatol Surg Oncol 1992; 18:17.</a></li><li><a class="nounderline abstract_t">Carruthers A, Carruthers J, Said S. Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females. Dermatol Surg 2005; 31:414.</a></li><li><a class="nounderline abstract_t">Carruthers A, Carruthers J. Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids. Dermatol Surg 2005; 31:1297.</a></li><li><a class="nounderline abstract_t">Carruthers JD, Glogau RG, Blitzer A, Facial Aesthetics Consensus Group Faculty. Advances in facial rejuvenation: botulinum toxin type a, hyaluronic acid dermal fillers, and combination therapies--consensus recommendations. Plast Reconstr Surg 2008; 121:5S.</a></li><li><a class="nounderline abstract_t">Kane M, Donofrio L, Ascher B, et al. Expanding the use of neurotoxins in facial aesthetics: a consensus panel's assessment and recommendations. J Drugs Dermatol 2010; 9:s7.</a></li><li><a class="nounderline abstract_t">Carruthers A, Carruthers J, Cohen J. A prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides. Dermatol Surg 2003; 29:461.</a></li><li><a class="nounderline abstract_t">Lowe NJ, Ascher B, Heckmann M, et al. Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet. Dermatol Surg 2005; 31:257.</a></li><li><a class="nounderline abstract_t">Prager W, Wissmüller E, Kollhorst B, et al. Comparison of two botulinum toxin type A preparations for treating crow's feet: a split-face, double-blind, proof-of-concept study. Dermatol Surg 2010; 36 Suppl 4:2155.</a></li><li><a class="nounderline abstract_t">Lowe NJ, Lask G, Yamauchi P, Moore D. Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet. J Am Acad Dermatol 2002; 47:834.</a></li><li><a class="nounderline abstract_t">Frankel AS, Kamer FM. Chemical browlift. Arch Otolaryngol Head Neck Surg 1998; 124:321.</a></li><li><a class="nounderline abstract_t">Huilgol SC, Carruthers A, Carruthers JD. Raising eyebrows with botulinum toxin. Dermatol Surg 1999; 25:373.</a></li><li><a class="nounderline abstract_t">Carruthers A, Carruthers J. Eyebrow height after botulinum toxin type A to the glabella. Dermatol Surg 2007; 33:S26.</a></li><li><a class="nounderline abstract_t">Maas CS, Kim EJ. Temporal brow lift using botulinum toxin A: an update. Plast Reconstr Surg 2003; 112:109S.</a></li><li><a class="nounderline abstract_t">Ahn MS, Catten M, Maas CS. Temporal brow lift using botulinum toxin A. Plast Reconstr Surg 2000; 105:1129.</a></li><li><a class="nounderline abstract_t">Flynn TC, Carruthers JA, Carruthers JA. Botulinum-A toxin treatment of the lower eyelid improves infraorbital rhytides and widens the eye. Dermatol Surg 2001; 27:703.</a></li><li><a class="nounderline abstract_t">Flynn TC, Carruthers JA, Carruthers JA, Clark RE 2nd. Botulinum A toxin (BOTOX) in the lower eyelid: dose-finding study. Dermatol Surg 2003; 29:943.</a></li><li><a class="nounderline abstract_t">Carruthers J, Carruthers A. Aesthetic botulinum A toxin in the mid and lower face and neck. Dermatol Surg 2003; 29:468.</a></li><li><a class="nounderline abstract_t">Carruthers J, Carruthers A. BOTOX use in the mid and lower face and neck. Semin Cutan Med Surg 2001; 20:85.</a></li><li><a class="nounderline abstract_t">Fagien S. Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: adjunctive use in facial aesthetic surgery. Plast Reconstr Surg 1999; 103:701.</a></li><li><a class="nounderline abstract_t">Fagien S. Botulinum toxin type A for facial aesthetic enhancement: role in facial shaping. Plast Reconstr Surg 2003; 112:6S.</a></li><li><a class="nounderline abstract_t">Semchyshyn N, Sengelmann RD. Botulinum toxin A treatment of perioral rhytides. Dermatol Surg 2003; 29:490.</a></li><li><a class="nounderline abstract_t">Carruthers A, Carruthers J, Monheit GD, et al. Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation. Dermatol Surg 2010; 36 Suppl 4:2121.</a></li><li><a class="nounderline abstract_t">Carruthers J, Carruthers A, Monheit GD, Davis PG. Multicenter, randomized, parallel-group study of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation: satisfaction and patient-reported outcomes. Dermatol Surg 2010; 36 Suppl 4:2135.</a></li><li><a class="nounderline abstract_t">Custis T, Beynet D, Carranza D, et al. Comparison of treatment of melomental fold rhytides with cross-linked hyaluronic acid combined with onabotulinumtoxina and cross-linked hyaluronic acid alone. Dermatol Surg 2010; 36 Suppl 3:1852.</a></li><li><a class="nounderline abstract_t">Yu CC, Chen PK, Chen YR. Botulinum toxin a for lower facial contouring: a prospective study. Aesthetic Plast Surg 2007; 31:445.</a></li><li><a class="nounderline abstract_t">Baş B, Ozan B, Muğlali M, Celebi N. Treatment of masseteric hypertrophy with botulinum toxin: a report of two cases. Med Oral Patol Oral Cir Bucal 2010; 15:e649.</a></li><li><a class="nounderline abstract_t">Al-Muharraqi MA, Fedorowicz Z, Al Bareeq J, et al. Botulinum toxin for masseter hypertrophy. Cochrane Database Syst Rev 2009; :CD007510.</a></li><li><a class="nounderline abstract_t">Fedorowicz Z, van Zuuren EJ, Schoones J. Botulinum toxin for masseter hypertrophy. Cochrane Database Syst Rev 2013; :CD007510.</a></li><li><a class="nounderline abstract_t">To EW, Ahuja AT, Ho WS, et al. A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement. Br J Plast Surg 2001; 54:197.</a></li><li><a class="nounderline abstract_t">von Lindern JJ, Niederhagen B, Appel T, et al. Type A botulinum toxin for the treatment of hypertrophy of the masseter and temporal muscles: an alternative treatment. Plast Reconstr Surg 2001; 107:327.</a></li><li><a class="nounderline abstract_t">Park MY, Ahn KY, Jung DS. Botulinum toxin type A treatment for contouring of the lower face. Dermatol Surg 2003; 29:477.</a></li><li><a class="nounderline abstract_t">Liew S, Dart A. Nonsurgical reshaping of the lower face. Aesthet Surg J 2008; 28:251.</a></li><li><a class="nounderline abstract_t">Chikhani L, Dichamp J. [Bruxism, temporo-mandibular dysfunction and botulinum toxin]. Ann Readapt Med Phys 2003; 46:333.</a></li><li><a class="nounderline abstract_t">Kim NH, Park RH, Park JB. Botulinum toxin type A for the treatment of hypertrophy of the masseter muscle. Plast Reconstr Surg 2010; 125:1693.</a></li><li><a class="nounderline abstract_t">Kim KS, Byun YS, Kim YJ, Kim ST. Muscle weakness after repeated injection of botulinum toxin type A evaluated according to bite force measurement of human masseter muscle. Dermatol Surg 2009; 35:1902.</a></li><li><a class="nounderline abstract_t">Mazzuco R, Hexsel D. Gummy smile and botulinum toxin: a new approach based on the gingival exposure area. J Am Acad Dermatol 2010; 63:1042.</a></li><li><a class="nounderline abstract_t">Polo M. Botulinum toxin type A (Botox) for the neuromuscular correction of excessive gingival display on smiling (gummy smile). Am J Orthod Dentofacial Orthop 2008; 133:195.</a></li><li><a class="nounderline abstract_t">Polo M. Botulinum toxin type A in the treatment of excessive gingival display. Am J Orthod Dentofacial Orthop 2005; 127:214.</a></li><li><a class="nounderline abstract_t">Li Y, Chong Y, Yu N, et al. The use of botulinum toxin A in upper lip augmentation. J Cosmet Dermatol 2021; 20:71.</a></li><li><a class="nounderline abstract_t">Teixeira JC, Ostrom JY, Hohman MH, Nuara MJ. Botulinum Toxin Type-A for Lip Augmentation: "Lip Flip". J Craniofac Surg 2021; 32:e273.</a></li><li><a class="nounderline abstract_t">Matarasso A, Matarasso SL, Brandt FS, Bellman B. Botulinum A exotoxin for the management of platysma bands. Plast Reconstr Surg 1999; 103:645.</a></li><li><a class="nounderline abstract_t">Kane MA. Nonsurgical treatment of platysmal bands with injection of botulinum toxin A. Plast Reconstr Surg 1999; 103:656.</a></li><li><a class="nounderline abstract_t">Brandt FS, Bellman B. Cosmetic use of botulinum A exotoxin for the aging neck. Dermatol Surg 1998; 24:1232.</a></li><li><a class="nounderline abstract_t">Brandt FS, Boker A. Botulinum toxin for the treatment of neck lines and neck bands. Dermatol Clin 2004; 22:159.</a></li><li><a class="nounderline abstract_t">Carruthers J, Carruthers A. Botulinum toxin A in the mid and lower face and neck. Dermatol Clin 2004; 22:151.</a></li><li><a class="nounderline abstract_t">Carruthers J, Carruthers A. Practical cosmetic Botox techniques. J Cutan Med Surg 1999; 3 Suppl 4:S49.</a></li><li><a class="nounderline abstract_t">Jeong SY, Park KY, Seok J, et al. Botulinum toxin injection for contouring shoulder. J Eur Acad Dermatol Venereol 2017; 31:e46.</a></li><li><a class="nounderline abstract_t">Han KH, Joo YH, Moon SE, Kim KH. Botulinum toxin A treatment for contouring of the lower leg. J Dermatolog Treat 2006; 17:250.</a></li><li><a class="nounderline abstract_t">Lee HJ, Lee DW, Park YH, et al. Botulinum toxin a for aesthetic contouring of enlarged medial gastrocnemius muscle. Dermatol Surg 2004; 30:867.</a></li></ol></div><div id="topicVersionRevision">Topic 16222 Version 16.0</div></div>
<div class="row">
<div class="col-12">
<h4 style="text-align: center;padding: 20px;color: cadetblue;">References</h4>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19686365" id="rid0" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>1 : Efficacy and safety of botulinum toxin type A in the treatment of lateral crow's feet: double-blind, placebo-controlled, dose-ranging study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12063480" id="rid1" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>2 : A multicenter, double-blind, randomized, placebo-controlled study of the efficacy and safety of botulinum toxin type A in the treatment of glabellar lines.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/1740562" id="rid2" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>3 : Treatment of glabellar frown lines with C. botulinum-A exotoxin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15871316" id="rid3" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>4 : Dose-ranging study of botulinum toxin type A in the treatment of glabellar rhytids in females.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16188182" id="rid4" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>5 : Prospective, double-blind, randomized, parallel-group, dose-ranging study of botulinum toxin type A in men with glabellar rhytids.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18449026" id="rid5" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>6 : Advances in facial rejuvenation: botulinum toxin type a, hyaluronic acid dermal fillers, and combination therapies--consensus recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20919448" id="rid6" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>7 : Expanding the use of neurotoxins in facial aesthetics: a consensus panel's assessment and recommendations.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12752512" id="rid7" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>8 : A prospective, double-blind, randomized, parallel- group, dose-ranging study of botulinum toxin type a in female subjects with horizontal forehead rhytides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15841623" id="rid8" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>9 : Double-blind, randomized, placebo-controlled, dose-response study of the safety and efficacy of botulinum toxin type A in subjects with crow's feet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21134046" id="rid9" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>10 : Comparison of two botulinum toxin type A preparations for treating crow's feet: a split-face, double-blind, proof-of-concept study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12451366" id="rid10" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>11 : Bilateral, double-blind, randomized comparison of 3 doses of botulinum toxin type A and placebo in patients with crow's feet.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9525518" id="rid11" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>12 : Chemical browlift.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10469075" id="rid12" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>13 : Raising eyebrows with botulinum toxin.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17241411" id="rid13" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>14 : Eyebrow height after botulinum toxin type A to the glabella.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14504491" id="rid14" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>15 : Temporal brow lift using botulinum toxin A: an update.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/10724275" id="rid15" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>16 : Temporal brow lift using botulinum toxin A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11493292" id="rid16" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>17 : Botulinum-A toxin treatment of the lower eyelid improves infraorbital rhytides and widens the eye.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12930337" id="rid17" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>18 : Botulinum A toxin (BOTOX) in the lower eyelid: dose-finding study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12752513" id="rid18" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>19 : Aesthetic botulinum A toxin in the mid and lower face and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11474748" id="rid19" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>20 : BOTOX use in the mid and lower face and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9950563" id="rid20" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>21 : Botox for the treatment of dynamic and hyperkinetic facial lines and furrows: adjunctive use in facial aesthetic surgery.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/14504481" id="rid21" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>22 : Botulinum toxin type A for facial aesthetic enhancement: role in facial shaping.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12752516" id="rid22" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>23 : Botulinum toxin A treatment of perioral rhytides.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21134044" id="rid23" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>24 : Multicenter, randomized, parallel-group study of the safety and effectiveness of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21070457" id="rid24" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>25 : Multicenter, randomized, parallel-group study of onabotulinumtoxinA and hyaluronic acid dermal fillers (24-mg/ml smooth, cohesive gel) alone and in combination for lower facial rejuvenation: satisfaction and patient-reported outcomes.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20969662" id="rid25" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>26 : Comparison of treatment of melomental fold rhytides with cross-linked hyaluronic acid combined with onabotulinumtoxina and cross-linked hyaluronic acid alone.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/17674088" id="rid26" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>27 : Botulinum toxin a for lower facial contouring: a prospective study.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20173718" id="rid27" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>28 : Treatment of masseteric hypertrophy with botulinum toxin: a report of two cases.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19160335" id="rid28" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>29 : Botulinum toxin for masseter hypertrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/24018587" id="rid29" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>30 : Botulinum toxin for masseter hypertrophy.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11254408" id="rid30" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>31 : A prospective study of the effect of botulinum toxin A on masseteric muscle hypertrophy with ultrasonographic and electromyographic measurement.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11214045" id="rid31" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>32 : Type A botulinum toxin for the treatment of hypertrophy of the masseter and temporal muscles: an alternative treatment.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12752514" id="rid32" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>33 : Botulinum toxin type A treatment for contouring of the lower face.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19083534" id="rid33" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>34 : Nonsurgical reshaping of the lower face.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/12928140" id="rid34" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>35 : [Bruxism, temporo-mandibular dysfunction and botulinum toxin].</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/20517093" id="rid35" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>36 : Botulinum toxin type A for the treatment of hypertrophy of the masseter muscle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/19737290" id="rid36" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>37 : Muscle weakness after repeated injection of botulinum toxin type A evaluated according to bite force measurement of human masseter muscle.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/21093661" id="rid37" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>38 : Gummy smile and botulinum toxin: a new approach based on the gingival exposure area.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/18249285" id="rid38" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>39 : Botulinum toxin type A (Botox) for the neuromuscular correction of excessive gingival display on smiling (gummy smile).</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15750541" id="rid39" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>40 : Botulinum toxin type A in the treatment of excessive gingival display.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/32969573" id="rid40" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>41 : The use of botulinum toxin A in upper lip augmentation.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/33170825" id="rid41" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>42 : Botulinum Toxin Type-A for Lip Augmentation: "Lip Flip".</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9950556" id="rid42" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>43 : Botulinum A exotoxin for the management of platysma bands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9950557" id="rid43" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>44 : Nonsurgical treatment of platysmal bands with injection of botulinum toxin A.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/9834744" id="rid44" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>45 : Cosmetic use of botulinum A exotoxin for the aging neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15222576" id="rid45" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>46 : Botulinum toxin for the treatment of neck lines and neck bands.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15222575" id="rid46" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>47 : Botulinum toxin A in the mid and lower face and neck.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/11749899" id="rid47" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>48 : Practical cosmetic Botox techniques.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/27615707" id="rid48" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>49 : Botulinum toxin injection for contouring shoulder.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/16971324" id="rid49" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>50 : Botulinum toxin A treatment for contouring of the lower leg.</p>
</a>
</div>
<div class="col-12" style="text-align: left;direction: ltr">
<a href="https://pubmed.ncbi.nlm.nih.gov/15171764" id="rid50" target="_blank">
<p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>51 : Botulinum toxin a for aesthetic contouring of enlarged medial gastrocnemius muscle.</p>
</a>
</div>
</div>
</div>
</div>

</section>

</section>
<!-- End Main Menu Area -->
<!-- Start Search Popup Area -->


<!-- End Footer Area -->
<!-- Back to top -->

<a class="scrolltop" href="#top"><i class="icofont-hand-drawn-up"></i></a>
<!-- End Back to top -->
<!-- jQuery Min JS -->

<!-- Prpper JS -->

<!-- Bootstrap Min JS -->

<!-- Classy Nav Min Js -->

<!-- Owl Carousel Min Js -->

<!-- Magnific Popup JS -->

<!-- CounterUp JS -->

<!-- Waypoints JS -->

<!-- Form Validator Min JS -->

<!-- Contact Form Min JS -->

<!-- Main JS -->

<!-- Global site tag (gtag.js) - Google Analytics -->






</body>
</html>
